Considering the efficient activity of GADD45G in triggering HCC cell senescence and suppressing tumor growth, pharmacological activation of GADD45G-SIP1 pathway may have a therapeutic potential for HCC patients, especially for those with the defects in p53/p16 or Rb pathways. The gene discussed is ZEB2; the disease is neoplasm.